Ferroptosis in ALS motor neuron vulnerability
Three mechanisms deserve priority: loss of GPX4 reserve in stressed motor neurons, ACSL4/LPCAT3-driven enrichment of oxidizable PUFA phospholipids, and genotype-specific iron mishandling in SOD1/TDP-43/FUS disease states. Each is testable with lipidomics plus ferroptosis-rescue controls.
The key weakness is causal ordering. Lipid peroxidation appears in many dying neurons, so experiments must show that ferroptosis blockade rescues motor-neuron survival after controlling for apoptosis, necroptosis, mitochondrial collapse, and inflammatory toxicity.
Translation requires biomarkers before treatment trials: CSF/plasma 4-HNE, F2-isoprostanes, oxidized PE species, GPX4 activity, and iron MRI should stratify patients. Deferiprone-like strategies need careful anemia and mitochondrial safety monitoring.
Ranked synthesis: prioritize GPX4 reserve failure, then PUFA-phospholipid substrate loading, then labile iron pool expansion. The program should demand orthogonal death-pathway exclusion and genotype-aware rescue studies.